The evaluation in the efficacy of Radium-223 for overall survival among patients with mCRPC: A meta-analysis

Yen-Hsiang Chang¹, Hao-Lun Luo², Li-Yu Chen³, Shiang-Ling Lin³, Ya-Ting Huang³

¹Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan
²Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Taiwan
³Primo Biotechnology Co., Ltd, Taipei, Taiwan

This meta-analysis was presented at the 2024 Annual Meeting of the Taiwan Urological Association(2024 TUA).

Radium-223 is the first FDA-approved bone-targeting internal alpha particle-emitting radiotherapeutic agent and helps to delay symptomatic skeletal events and significantly improve quality of life. 

Several studies have shown that radium-223 can effectively improve overall survival. 

According to this meta-analysis, mCRPC patients who underwent 5-6 cycles of radium-223 treatment or combine it with androgen deprivation therapy (ADT) or chemotherapy (C/T) experienced improvements in overall survival. Although a significant difference in overall survival between radium-223 and placebo has not yet been observed, these analysis results still offer valuable insights for prostate cancer  treatment.